Datapoint: FDA Expands Otezla’s Psoriasis Label

The FDA last month expanded the patient population of Amgen Inc.’s Otezla (apremilast) to include the treatment of people between 6 and 17 years old and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. The agency first approved the phosphodiesterase 4 (PDE4) inhibitor on March 21, 2014. Dosing for the new patient population of the tablet is 30 mg twice daily for people weighing at least 50 kg; for those at least 20 kg and less than 50 kg, dosing is 20 mg twice daily. For the treatment of psoriasis, virtually all insured lives have covered or better access to Otezla. 48% of covered lives have preferred access to Otezla, largely with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 5/13/24

0

0

0 Comments

0

0

• Datapoint